Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb open-label study of rilzabrutinib in warm autoimmune hemolytic anemia
CTR20212864Phase 2Active
- Sponsor
- Sanofi
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rilzabrutinib in warm autoimmune hemolytic anemia (wAIHA), sponsored by Sanofi. Started Jan 2022; status: active.
02
Drugs
rilzabrutinib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on CTR20212864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212864.